기분부전증과 비전형우울증의 약물치료
Pharmacological treatments for Dysthymia and Atypical depression
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Objectives: The diagnosis of depression is based on a highly variable set of symptoms. Therefore, depression should not be viewed as single disease, but a heterogenous syndrome comprised of different pathophysiologies. There are several subtypes of depression which already incorporated in DSM-IV. This article provides a systematic review of pharmacological treatments of two recognized subtypes of depression-dysthymic disorder and atypical depression. Methods: Systematic search of relevant literatures on dysthymic disorder and atypical depression was performed by proposed search strategy of the Clinical Research Center for Depression of Korean Health 21 R&D Project. All identified literatures carefully reviewd and classified according to SIGN grading system and summarized in a narrative manner.Results: For the treatment of dysthymia and atypical depression, selective serotonin reuptake inhibitors(SSRIs) and moclobemide have more evidence than the other antidepressants. SSRIs and moclobemide showed superior tolerability than tricyclic antidepressants. Conclusions: The authors proposed treatment recommendations for dysthymic disorder and atypical depression by the methods of evidence-based medicine(EBM). However, guideline developing methods of EBM also have several inevitable limitations. Therefore, in the absence of clear and significant differences in efficacy, the choice of medication must be individualized for a particular patient based on psychiatrist's own clinical decision.
참고문헌 (32)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (1994), American Psychiatric Press
- Korean Neuropsychiatric Association, "Textbook of Neuropsychiatry", pp.179~181 (2005), Seoul: Jungang Moonwha
- Quitkin FM, "Columbia atypical depression", 21, pp.30~34 (1993)
- Scottish Intercollegiate Guideline Network, "A Guideline Developer's Handbook." (2002), Edinburgh; Scottish Intercollegiate Guideline Network
- Henkel V, "Treatment of depression with atypical features: a meta-analytic approach.", 141(1), pp.89~101 (2006)
- Lima MS, "Pharmacotherapy for dysthymia(review).", 2 (2006)
- Lima MS, "Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.", 26(1), pp.55~64 (2003)
- Hays RD, "Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses.", 52(1), pp.11~19 (1995)
- Thase ME, "A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.", 53(9), pp.777~84 (1996)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders(DSM-III-R)." (1987), American Psychiatric Press
- Versiani M, "Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial.", 12(4), pp.183~93 (1997)
- Barrett JE, "Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.", 50(5), pp.405~12 (2001)
- Hellerstein DJ, "A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia", ya(witch p), pp.1169~75 (1993)
- Hellerstein DJ, "Citalopram in the treatment of dysthymic disorder.", 19(3), pp.143~148 (2004)
- Hellerstein DJ, "Venlafaxine in the treatment of dysthymia: an open-label study.", 60(12), pp.845~849 (1999)
- Dunner DL, "Dysthymic disorder: treatment with mirtazapine.", 10(2), pp.68~72 (1999)
- Hellerstein DJ, "Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study.", 21(3), pp.325~9 (2001)
- Amore M, Jori MC, "Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study.", 16(6), pp.317~24 (2001)
- Ravizza L, "Amisulpiride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline.", 13(3), pp.248~254 (1999)
- West ED, "Effects of iproniazid in depressive syndromes", pp.1491~1494 (1959)
- Davidson J, "Forms of atypical depression and their response to antidepressant drugs", pp.87~95 (1986)
- Parker RR, "Nosology of atypical depression", pp.131~139 (1983)
- Nierenberg AA, "Course and treatment of atypical depression.", 59, pp.5~9 (1998)
- Quitkin FM, "Response to phenelzine and imipramine in placebo nonresponders with atypical depression A new application of the crossover design", pp.319~23 (1991)
- Stewart JW, "Phenelzine versus imipramine in the treatment of probable atypical depression defining syndrome boundaries of selective MAOI responders", pp.306~11 (1988)
- Kiviruusu O, "Moclobemide and fluoxetine in atypical depression", pp.169~77 (1994)
- Sogaard J, "A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.", 13(4), pp.406~14 (1999)
- Anderson IM, "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.", 58(1), pp.19~36 (2000)
- Roose SP, "An open trial of venlafaxine for the treatment of late-life atypical depression.", 19(10), pp.989~994 (2004)
- Freemantle N, "Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.", 177, pp.292~302 (2000)
- Sackett DL, "Evidence based medicine: How to practice and teach EBM." (1997), Edinburg: Churchill livingstone
- Akiskal HS, "Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?", 84(2-3), pp.209~217 (2005)